Serban Puricel
Serban Puricel has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Jacques Goy
Clinique Cecil, Lausanne, Switzerland
6 shared publications - Stéphane Cook
Department of Cardiology, HFR—Fribourg Cantonal Hospital and University, 1708 Fribourg, Switzerland
6 shared publications Diego Arroyo
Hospital & University Fribourg, Fribourg, Switzerland
5 shared publicationsZacharenia Kallinikou
Department of Cardiology, University and Hospital Fribourg, Fribourg, Switzerland
5 shared publications- Mario Togni
Swiss Cardiovascular Center Bern, Inselspital, CH-3010 Bern, Switzerland
4 shared publications Stéphane Cook
Department of Cardiology, University and Hospital Fribourg, Fribourg, Switzerland
4 shared publications
Latest Publications
- Open Access
- 3 January 2018
- Published by BMJ in Open Heart
- Vol. 5 (1) , e000624
Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial
Aims To compare endothelium-dependent vasomotor function and vascular healing 15 months after implantation of two new-generation drug-eluting stents and biovascular scaffolds (BVS). Methods and results A total of 28 patients previously treated with a SYNERGY stent (bioabsorbable polymer everolimus-eluting stents (BP-EES)), a PROMUS stent (persistent polymer everolimus-eluting stents (PP-EES)) or an ABSORB (BVS) underwent control coronary angiography, 15 months after implantation, coupled with optical coherence tomography imaging and supine bicycle exercise. Intracoronary nitroglycerin was administered after exercise testing. Coronary vasomotor response was assessed using quantitative coronary angiography at rest, during supine bicycle exercise and after nitroglycerin. The primary end point was the percent change in mean lumen diameter compared with baseline. Secondary end points were strut coverage and apposition. There were no significant differences in vasomotor response between the three treatment groups. Patients with PP-EES showed significant vasoconstriction of the proximal peristent segment at maximum exercise (P=0.02). BP-EES (2.7%, 95% CI 0 to 5.5) and BVS (3.2%, 95% CI 0 to 6.7) showed less uncovered struts than PP-EES (12.1%, 95% CI 2.9 to 21.3, P=0.02 and 0.09, respectively). Complete strut apposition was more frequently seen with BP-EES (99.6%, 95% CI 99.2 to 100) than with BVS (98.9%, 95% CI 98.2 to 99.6, P=0.04) or PP-EES (95.0%, 95% CI 91.6 to 98.5, P=0.001). Conclusion BVS and thin strut BP-EES have a reassuring vasomotion profile, suggesting minimal endothelial dysfunction 15 months after implantation.
- 3 January 2018
- Published by BMJ in Open Heart
- Vol. 5 (1) , e000624
Open AccessMultianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial
Aims To compare endothelium-dependent vasomotor function and vascular healing 15 months after implantation of two new-generation drug-eluting stents and biovascular scaffolds (BVS). Methods and results A total of 28 patients previously treated with a SYNERGY stent (bioabsorbable polymer everolimus-eluting stents (BP-EES)), a PROMUS stent (persistent polymer everolimus-eluting stents (PP-EES)) or an ABSORB (BVS) underwent control coronary angiography, 15 months after implantation, coupled with optical coherence tomography imaging and supine bicycle exercise. Intracoronary nitroglycerin was administered after exercise testing. Coronary vasomotor response was assessed using quantitative coronary angiography at rest, during supine bicycle exercise and after nitroglycerin. The primary end point was the percent change in mean lumen diameter compared with baseline. Secondary end points were strut coverage and apposition. There were no significant differences in vasomotor response between the three treatment groups. Patients with PP-EES showed significant vasoconstriction of the proximal peristent segment at maximum exercise (P=0.02). BP-EES (2.7%, 95% CI 0 to 5.5) and BVS (3.2%, 95% CI 0 to 6.7) showed less uncovered struts than PP-EES (12.1%, 95% CI 2.9 to 21.3, P=0.02 and 0.09, respectively). Complete strut apposition was more frequently seen with BP-EES (99.6%, 95% CI 99.2 to 100) than with BVS (98.9%, 95% CI 98.2 to 99.6, P=0.04) or PP-EES (95.0%, 95% CI 91.6 to 98.5, P=0.001). Conclusion BVS and thin strut BP-EES have a reassuring vasomotion profile, suggesting minimal endothelial dysfunction 15 months after implantation.
- 31 May 2016
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 8 (6) , E431-E436
Bioresorbable vascular scaffolds—time to vanish?
The fully bioabsorbable vascular scaffold (BVS) has been developed to reduce late adverse events after coronary stenting such as device thrombosis. The device consists of polylactic acid, which is gradually absorbed within the first few years after its implantation. The initial experience with the device in low-risk patients presenting with simple lesions was satisfying and generated optimism among interventional cardiologists by promising better patient outcomes. However, the unrestricted use of the device in patients presenting with a higher baseline risk and more complex lesions came at the cost of alarmingly high rates of early device thrombosis. The performance of the device largely depends on an optimal implantation technique, which differs from that employed with metallic drug-eluting stents due to the device’s distinct physical propensity. Mid-term outcomes in large-scale randomized clinical trial were disappointing. Although its non-inferiority compared to metallic everolimus-eluting stents was formally met, there was a clear trend towards an increased occurrence of myocardial infarction and device thrombosis during the first year after device implantation. However, the BVS’s putative advantages are expected to manifest themselves at long-term, that is 3 to 5 years after the device has been implanted. Evidence pertaining to these long-term outcomes is eagerly awaited.
- 31 May 2016
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 8 (6) , E431-E436
Bioresorbable vascular scaffolds—time to vanish?
The fully bioabsorbable vascular scaffold (BVS) has been developed to reduce late adverse events after coronary stenting such as device thrombosis. The device consists of polylactic acid, which is gradually absorbed within the first few years after its implantation. The initial experience with the device in low-risk patients presenting with simple lesions was satisfying and generated optimism among interventional cardiologists by promising better patient outcomes. However, the unrestricted use of the device in patients presenting with a higher baseline risk and more complex lesions came at the cost of alarmingly high rates of early device thrombosis. The performance of the device largely depends on an optimal implantation technique, which differs from that employed with metallic drug-eluting stents due to the device’s distinct physical propensity. Mid-term outcomes in large-scale randomized clinical trial were disappointing. Although its non-inferiority compared to metallic everolimus-eluting stents was formally met, there was a clear trend towards an increased occurrence of myocardial infarction and device thrombosis during the first year after device implantation. However, the BVS’s putative advantages are expected to manifest themselves at long-term, that is 3 to 5 years after the device has been implanted. Evidence pertaining to these long-term outcomes is eagerly awaited.
- 25 March 2016
- Published by Springer Nature
- p. 649-653
Bioresorbable Vascular Scaffolds in the Treatment of Coronary Artery Bypass Grafts
- 25 March 2016
- Published by Springer Nature
- p. 649-653
Bioresorbable Vascular Scaffolds in the Treatment of Coronary Artery Bypass Grafts
- 1 February 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (4) , S21-S22
CRT-200.60 Multi-analysis With Oct and Vasomotion in Everolimus-eluting Synergy Coronary Stents - The Moves Trial
- 1 February 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (4) , S21-S22
CRT-200.60 Multi-analysis With Oct and Vasomotion in Everolimus-eluting Synergy Coronary Stents - The Moves Trial
- Open Access
- 15 September 2015
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 17 (1) , 12-14
Coronary healing after stenting: wounds, faith, and the quest for the perfect stent
- 15 September 2015
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 17 (1) , 12-14
Open AccessCoronary healing after stenting: wounds, faith, and the quest for the perfect stent
- 1 June 2015
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 11 (2) , 230-237
A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION)
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 June 2015
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 11 (2) , 230-237
A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION)
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)